COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS

摘要

Bergamottin, a principle compound in grapefruit juice responsible for inhibition of P450 3A4, the predominant P450 enzyme in the intestine, is coadministered with a compound having low bioavailability to a patient to increase oral bioavailability of the compound and pharmaceutical compositions of the same, as well as a method of isolating BG from grapefruit juice.